Dragana Nikolic
Overview
Explore the profile of Dragana Nikolic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
1761
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bryant J, Birch A, Panerai R, Nikolic D, Bulters D, Simpson D
Physiol Meas
. 2021 Sep;
42(10).
PMID: 34534969
Cerebral autoregulation (CA) refers to the ability of the brain vasculature to control blood flow in the face of changing blood pressure. One of the methods commonly used to assess...
12.
Raimondo S, Nikolic D, Conigliaro A, Giavaresi G, Lo Sasso B, Giglio R, et al.
Metabolites
. 2021 Apr;
11(5).
PMID: 33925596
Appropriate monitoring and control of modifiable risk factors, such as the level of low-density lipoprotein cholesterol (LDL-C) and other types of dyslipidemia, have an important role in the prevention of...
13.
Nikolic D, Milkovic D, Jurisic V
Acta Clin Croat
. 2021 Jan;
59(2):368-372.
PMID: 33456127
Acute osteomyelitis is pyogenic infection of the bone and bone marrow. We report a case of successful diagnosis and treatment in a 12-year-old boy with right shoulder joint osteoarthritis. On...
14.
Stoica R, Diaconu C, Rizzo M, Toth P, Stefan S, Serafinceanu C, et al.
Exp Ther Med
. 2020 Dec;
21(1):90.
PMID: 33363601
Cardiovascular risk (CVR) is a broad term that includes traditional factors like hypertension, hyper lipidemia, abdominal obesity, hyperinsulinemia or overt type 2 diabetes mellitus (T2DM), and emerging ones such as...
15.
Nikolic D, Giglio R, Rizvi A, Patti A, Montalto G, Maranta F, et al.
Diabetes Ther
. 2020 Nov;
12(1):261-274.
PMID: 33210276
Introduction: Liraglutide has several non-glycemic effects, including those on plasma lipids and lipoproteins, contributing to its cardiovascular benefit; however, the exact underlying mechanisms remain unclear. We investigated a novel anti-atherogenic...
16.
Giglio R, Carruba G, Cicero A, Banach M, Patti A, Nikolic D, et al.
Metabolites
. 2020 Oct;
10(11).
PMID: 33114614
Food supplementation with (OFI) has been associated with a significant reduction in total cholesterol, body fat, hyperglycemia and blood pressure. Since OFI may also have antioxidant and anti-atherogenic properties, we...
17.
Patti A, Carruba G, Cicero A, Banach M, Nikolic D, Giglio R, et al.
Metabolites
. 2020 Oct;
10(10).
PMID: 33023123
Extra virgin olive oil (EVOO) intake is associated with reduced cardiovascular risk, and its phenolic compound oleocanthal (OC) has anti-oxidant and anti-inflammatory properties. The cardiometabolic effects of EVOO with a...
18.
Giglio R, Nikolic D, Volti G, Pantea Stoian A, Banerjee Y, Magan-Fernandez A, et al.
Metabolites
. 2020 Oct;
10(10).
PMID: 33008044
Liraglutide has shown favourable effects on several cardiometabolic risk factors, beyond glucose control. MicroRNAs (miRNAs) regulate gene expression, resulting in post-transcriptional modifications of cell response and function. Specific miRNAs, including...
19.
Sachinidis A, Nikolic D, Pantea Stoian A, Papanas N, Tarar O, Rizvi A, et al.
Metabolism
. 2020 Aug;
111:154343.
PMID: 32810485
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors are so called "incretin-based therapies" (IBTs) that represent innovative therapeutic approaches and are commonly used in clinical practice for the...
20.
Pantea Stoian A, Sachinidis A, Stoica R, Nikolic D, Patti A, Rizvi A
Metabolism
. 2020 Jun;
109:154295.
PMID: 32553739
Introduction: The dipeptidyl peptidase-4 inhibitors (DPP-4is), which belong to the class of incretin-based medications, are recommended as second or third-line therapies in guidelines for the management of type 2 diabetes...